|Chemical and physical data|
|Molar mass||244.267 g/mol|
|3D model (Jmol)||Interactive image|
|(what is this?)|
BRL-50481 is a drug developed by GlaxoSmithKline which is the first compound that acts as a phosphodiesterase inhibitor selective for the PDE7 subtype. It has been shown to increase mineralisation activity in osteoblasts, suggesting a potential role for PDE7 inhibitors in the treatment of osteoporosis.
- Smith, SJ; Cieslinski, LB; Newton, R; Donnelly, LE; Fenwick, PS; Nicholson, AG; Barnes, PJ; Barnette, MS; Giembycz, MA (December 2004). "Discovery of BRL 50481 [3-(N,N-dimethylsulfonamido)-4-methyl-nitrobenzene], a Selective Inhibitor of Phosphodiesterase 7: in vitro Studies in Human Monocytes, Lung Macrophages, and CD8+ T-Lymphocytes" (PDF). Molecular Pharmacology. 66 (6): 1679–89. doi:10.1124/mol.104.002246. PMID 15371556. Retrieved 5 October 2016.
- Pekkinen, M; Ahlström, ME; Riehle, U; Huttunen, MM; Lamberg-Allardt, CJ (July 2008). "Effects of Phosphodiesterase 7 Inhibition by RNA Interference on the Gene Expression and Differentiation of Human Mesenchymal Stem Cell-Derived Osteoblasts". Bone. 43 (1): 84–91. doi:10.1016/j.bone.2008.02.021. PMID 18420479.